Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer

• Sponsor: University of Washington (Other)
• Overall Status: Completed
• CT.gov ID: NCT00331552
• Collaborator: National Cancer Institute (NCI) (NIH)
• Enrollment: 30
• Location: 1
• Arm: 1
• Duration (Months): 72
• Patients Per Site Per Month: 0.4

Study Details

Study Description

Brief Summary

Drugs used in chemotherapy, such as doxorubicin hydrochloride liposome and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving more than one drug (combination chemotherapy) together with trastuzumab may be a better way to block tumor growth.

Condition or Disease	Intervention/Treatment	Phase
HER2-positive Breast Cancer; Male Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer	Drug: pegylated liposomal doxorubicin hydrochloride; Drug: cyclophosphamide; Biological: trastuzumab	Phase 1/Phase 2

Detailed Description

PRIMARY OBJECTIVES: I. To determine the optimal tolerated dose of Doxil when given in combination with daily oral cyclophosphamide in patients with stage IV breast cancer. (Phase

1. 1. To determine the efficacy (overall clinical response rate) of the optimal tolerated dose of Doxil when given in combination with daily oral cyclophosphamide and herceptin (for HER2 neu positive patients) in patients with stage IV breast cancer. (Phase II) SECONDARY OBJECTIVES: I. To assess the treatment related toxicity associated with each dose level of this regimen and assess efficacy (overall clinical response rate). (Phase I) II. To assess the safety (treatment related toxicity) of the optimal tolerated dose of Doxil when given in combination with daily oral cyclophosphamide and herceptin (for HER2 neu positive patients) in patients with stage IV breast cancer. (Phase II) III. To assess time to progression and overall survival following treatment with Doxil and daily oral cyclophosphamide and herceptin (for HER2 neu positive patients). (Phase II) IV. To compare the response rate in patients who are heavily pretreated to the response rate in patients who are less heavily pretreated. OUTLINE: This is a phase I, dose-escalation study of pegylated doxorubicin HCl liposome followed by a phase II feasibility study. Patients receive oral cyclophosphamide once daily on days 1-28 and pegylated doxorubicin HCl liposome IV over 90 minutes on day 1. Treatment repeats every 4-6 weeks in the absence of disease progression or unacceptable toxicity. Some patients with HER2/neu 3+ disease may also receive trastuzumab IV over 30-90 minutes weekly or every 3 weeks at the discretion of the treating physician. After completion of study treatment, patients are followed up every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.

Study Design

• Study Type: Interventional
• Actual Enrollment: 30 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Phase I - II Study of Doxil® In Combination With Daily Oral Cyclophosphamide and Herceptin for Patients With HER-2/Neu Positive Disease In Patients With Metastatic Breast Cancer
• Study Start Date: Feb 1, 2006
• Actual Primary Completion Date: Feb 1, 2011
• Actual Study Completion Date: Feb 1, 2012

Arms and Interventions

Arm

Intervention/Treatment

Experimental: Arm I Patients receive oral cyclophosphamide once daily on days 1-28 and pegylated doxorubicin HCl liposome IV over 90 minutes on day 1. Treatment repeats every 4-6 weeks in the absence of disease progression or unacceptable toxicity. Some patients with HER2/neu 3+ disease may also receive trastuzumab IV over 30-90 minutes weekly or every 3 weeks at the discretion of the treating physician.

Drug: pegylated liposomal doxorubicin hydrochloride; Given IV; Other Names: CAELYX Dox-SL DOXIL doxorubicin hydrochloride liposome Evacet LipoDox ; Drug: cyclophosphamide; Given orally; Other Names: CPM CTX Cytoxan Endoxan Endoxana Enduxan ; Biological: trastuzumab; Given IV; Other Names: anti-c-erB-2 Herceptin MOAB HER2 monoclonal antibody c-erb-2 monoclonal antibody HER2

Outcome Measures

Primary Outcome Measures

1. Maximum Tolerated Dose and Optimal Tolerated Dose of Pegylated Liposomal Doxorubicin Hydrochloride (Doxil) When Given in Combination With Cyclophosphamide (Phase I) [Up to 24 weeks]

   The dose level in which 2 or more patients develop treatment-related toxicity of grade 3 or higher OR require a dose adjustment following the first course of treatment

2. Efficacy as Assessed by the Overall Clinical Benefit Rate [18 months]

   Count of participants with a clinical benefit (i.e., complete response, partial response, and stable disease).

3. Safety as Assessed by Grade 1, 2, 3, 4, Fatal Toxicity, Need for Dose Reduction, Treatment Interruption, or Treatment Discontinuation [Periodically during study treatment, up to 24 weeks]

   Count of participants with grade 1, 2, 3, 4, fatal toxicity, need for dose reduction, treatment interruption, or treatment discontinuation

Secondary Outcome Measures

1. Treatment-related Toxicity (Phase I) [Up to 24 weeks]

   Count of phase I participants with treatment related toxicity.

2. Time to Progression (Phase II) [Up to 2 years]

   Median time to progression. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions or new effusions.

3. Progression-free Survival (Phase II) [18 months]

   Kaplan-Meier estimate assessed at 18 months

4. Overall Survival (Phase II) [18 months]

   Kaplan-Meier estimate assessed at 18 months

5. Comparison of Clinical Benefit Rate in 2 Subgroups--heavily Pre-treated (1 or More Regimens for Advanced Disease) vs Less Heavily Pre-treated (no Regimens for Advanced Disease) (Phase II) [Up to 24 weeks]

   Count of participants with a clinical benefit (i.e., complete response, partial response, and stable disease).

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Patients must satisfy either a or b: a) Measurable disease by RECIST criteria; x-rays, scans or physical examinations used for tumor assessment must have been completed within 30 days prior to registration; any non-measurable disease must be assessed within 42 days prior to registration; b) Non-measurable disease only, but MUC-1 antigen level (either CA 27-29 or CEA) is > 2X ULN AND MUC-1 antigen has been documented to have increased by 1.5X prior to registration; x-rays, scans or other tests for assessment of non-measurable disease must have been performed within 42 days prior to registration

• ECOG performance status of =< 2

• ANC >= 1,500 cells/mm^3

• Platelet count >= 100,000 cells/mm^3

• Hemoglobin >= 9.0g/dL

• Creatinine =< 2.5 mg/dL

• In the absence of liver metastases, AST / ALT, alkaline phosphatase and total bilirubin must not exceed 2 x upper limit of normal (i.e., must be =< 2 x upper limit of normal)

• In the presence of liver metastases, AST / ALT, alkaline phosphatase and total bilirubin must not exceed 3 x upper limit of normal (i.e., must be =< 3 x upper limit of normal)

• Have a MUGA scan or 2-d echocardiogram indicating an ejection fraction of >= 50% within 42 days prior to first dose of study drug (the method used at baseline must be used for later monitoring)

• Use an adequate contraceptive method (e.g., abstinence, intrauterine device, barrier device with spermicide or surgical sterilization) during treatment and for three months after completing treatment if of reproductive potential

• Be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study specific screening procedures

Exclusion Criteria:

• Pregnant or lactating women

• History of hypersensitivity reactions attributed to a conventional formulation of doxorubicin HCL or the components of Doxil

• Patients who are HER2-neu positive with cardiac disease that would preclude the use of Doxil or Herceptin are not eligible, including active cardiac disease (i.e., angina pectoris that requires the use of antianginal medication, cardiac arrhythmia requiring medication, severe conduction abnormality, clinically significant valvular disease, cardiomegaly on chest x-ray, ventricular hypertrophy on EKG, uncontrolled hypertension [diastolic greater than 100 mm/Hg or systolic > 200 mm/hg], current use of digitalis or beta blockers for CHF, clinically significant pericardial effusion) and history of cardiac disease (i.e., myocardial infarction documented as a clinical diagnosis or by EKG or any other test, documented congestive heart failure, documented cardiomyopathy, documented arrhythmia or cardiac valvular disease that requires medication or is medically significant)

• Has anthracycline resistant disease defined as a) If anthracycline was given for non-metastatic disease: The cumulative dose of anthracycline exceeds 360 mg/m^ 2 for doxorubicin or 540 mg/m^{2 for epirubicin AND the disease-free interval from discontinuation of anthracycline to diagnosis of metastatic disease is < 12 months; b) If anthracycline was given for metastatic disease: The cumulative dose of anthracycline exceeds 360 mg/m}2 for doxorubicin or 540 mg/m^2 for epirubicin AND the patient's disease progressed on anthracycline given as palliative therapy

• Except for the following no other malignancy is allowed: synchronous ipsilateral breast cancer of the same subtype (ER/PR, HER-2/neu), adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer or other stage I or II cancer from which the patient has been disease free for at least 5 years

• Any life-threatening illness other than the malignancy for which they are being treated

• Mental illness

• Have a life expectancy of less than 4 months

• Unwillingness to participate or inability to comply with the protocol for the duration of the study

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium	Seattle	Washington	United States	98109

Sponsors and Collaborators

• University of Washington
• National Cancer Institute (NCI)

Investigators

• Principal Investigator: Hannah Linden, Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Hannah Linden, Principal Investigator, University of Washington
• ClinicalTrials.gov Identifier: NCT00331552
• Other Study ID Numbers: 6139; NCI-2010-00798
• First Posted: May 31, 2006
• Last Update Posted: Jul 26, 2017
• Last Verified: Jun 1, 2017

• Additional relevant MeSH terms: Breast Neoplasms; Breast Neoplasms, Male; Cyclophosphamide; Doxorubicin; Liposomal doxorubicin; Trastuzumab; Antineoplastic Agents, Immunological; Antibodies; Immunoglobulins; Antibodies, Monoclonal

Study Results

Participant Flow

Arm/Group Title	Cyclophosphamide, Doxil 30 mg/m^2, Trastuzumab	Cyclophosphamide, Doxil 35 mg/m^2, Trastuzumab
Arm/Group Description	Patients receive oral cyclophosphamide once daily on days 1-28 and 30 mg/m^2 pegylated doxorubicin HCl liposome IV over 90 minutes on day 1. Treatment repeats every 4-6 weeks in the absence of disease progression or unacceptable toxicity. Some patients with HER2/neu 3+ disease may also receive trastuzumab IV over 30-90 minutes weekly or every 3 weeks at the discretion of the treating physician. pegylated liposomal doxorubicin hydrochloride: Given IV cyclophosphamide: Given orally trastuzumab: Given IV	Patients receive oral cyclophosphamide once daily on days 1-28 and 35 mg/m^2 pegylated doxorubicin HCl liposome IV over 90 minutes on day 1. Treatment repeats every 4-6 weeks in the absence of disease progression or unacceptable toxicity. Some patients with HER2/neu 3+ disease may also receive trastuzumab IV over 30-90 minutes weekly or every 3 weeks at the discretion of the treating physician. pegylated liposomal doxorubicin hydrochloride: Given IV cyclophosphamide: Given orally trastuzumab: Given IV
Period Title: Period 1: Doxil 30 mg/m^2 (Phase I)
STARTED	3	0
COMPLETED	3	0
NOT COMPLETED	0	0
Period Title: Period 1: Doxil 30 mg/m^2 (Phase I)
STARTED	0	3
COMPLETED	0	3
NOT COMPLETED	0	0
Period Title: Period 1: Doxil 30 mg/m^2 (Phase I)
STARTED	24	0
COMPLETED	22	0
NOT COMPLETED	2	0

Baseline Characteristics

Arm/Group Title	Phase I: Cyclophosphamide, Doxil, Trastuzumab	Phase II: Cyclophosphamide, Doxil, Trastuzumab	Total
Arm/Group Description	Patients receive oral cyclophosphamide once daily on days 1-28 and pegylated doxorubicin HCl liposome IV over 90 minutes on day 1. Treatment repeats every 4-6 weeks in the absence of disease progression or unacceptable toxicity. Some patients with HER2/neu 3+ disease may also receive trastuzumab IV over 30-90 minutes weekly or every 3 weeks at the discretion of the treating physician. pegylated liposomal doxorubicin hydrochloride: Given IV cyclophosphamide: Given orally trastuzumab: Given IV	Patients receive oral cyclophosphamide once daily on days 1-28 and pegylated doxorubicin HCl liposome IV over 90 minutes on day 1. Treatment repeats every 4-6 weeks in the absence of disease progression or unacceptable toxicity. Some patients with HER2/neu 3+ disease may also receive trastuzumab IV over 30-90 minutes weekly or every 3 weeks at the discretion of the treating physician. pegylated liposomal doxorubicin hydrochloride: Given IV cyclophosphamide: Given orally trastuzumab: Given IV	Total of all reporting groups
Overall Participants	6	24	30
Age (years) [Median (Full Range) ]
Median (Full Range) [years]	49.5	57	56.5
Sex: Female, Male (Count of Participants)
Female	6 100%	23 95.8%	29 96.7%
Male	0 0%	1 4.2%	1 3.3%
Ethnicity (NIH/OMB) (Count of Participants)
Hispanic or Latino	0 0%	0 0%	0 0%
Not Hispanic or Latino	6 100%	24 100%	30 100%
Unknown or Not Reported	0 0%	0 0%	0 0%
Race (NIH/OMB) (Count of Participants)
American Indian or Alaska Native	0 0%	0 0%	0 0%
Asian	1 16.7%	1 4.2%	2 6.7%
Native Hawaiian or Other Pacific Islander	0 0%	0 0%	0 0%
Black or African American	1 16.7%	1 4.2%	2 6.7%
White	4 66.7%	21 87.5%	25 83.3%
More than one race	0 0%	1 4.2%	1 3.3%
Unknown or Not Reported	0 0%	0 0%	0 0%

Outcome Measures

1. Primary Outcome

Title	Maximum Tolerated Dose and Optimal Tolerated Dose of Pegylated Liposomal Doxorubicin Hydrochloride (Doxil) When Given in Combination With Cyclophosphamide (Phase I)
Description	The dose level in which 2 or more patients develop treatment-related toxicity of grade 3 or higher OR require a dose adjustment following the first course of treatment
Time Frame	Up to 24 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Phase I: Cyclophosphamide, Doxil, Trastuzumab
Arm/Group Description	Patients receive oral cyclophosphamide once daily on days 1-28 and pegylated doxorubicin HCl liposome IV over 90 minutes on day 1. Treatment repeats every 4-6 weeks in the absence of disease progression or unacceptable toxicity. Some patients with HER2/neu 3+ disease may also receive trastuzumab IV over 30-90 minutes weekly or every 3 weeks at the discretion of the treating physician. pegylated liposomal doxorubicin hydrochloride: Given IV cyclophosphamide: Given orally trastuzumab: Given IV
Measure Participants	6
Number [mg/m^2]	30

2. Primary Outcome

Title	Efficacy as Assessed by the Overall Clinical Benefit Rate
Description	Count of participants with a clinical benefit (i.e., complete response, partial response, and stable disease).
Time Frame	18 months

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Cyclophosphamide, Doxil, Trastuzumab
Arm/Group Description	Patients receive oral cyclophosphamide once daily on days 1-28 and pegylated doxorubicin HCl liposome IV over 90 minutes on day 1. Treatment repeats every 4-6 weeks in the absence of disease progression or unacceptable toxicity. Some patients with HER2/neu 3+ disease may also receive trastuzumab IV over 30-90 minutes weekly or every 3 weeks at the discretion of the treating physician. pegylated liposomal doxorubicin hydrochloride: Given IV cyclophosphamide: Given orally trastuzumab: Given IV
Measure Participants	28
Complete response	0 0%
Partial response	6 100%
Stable disease	15 250%
Progressive disease	7 116.7%

3. Primary Outcome

Title	Safety as Assessed by Grade 1, 2, 3, 4, Fatal Toxicity, Need for Dose Reduction, Treatment Interruption, or Treatment Discontinuation
Description	Count of participants with grade 1, 2, 3, 4, fatal toxicity, need for dose reduction, treatment interruption, or treatment discontinuation
Time Frame	Periodically during study treatment, up to 24 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Cyclophosphamide, Doxil, Trastuzumab
Arm/Group Description	Patients receive oral cyclophosphamide once daily on days 1-28 and pegylated doxorubicin HCl liposome IV over 90 minutes on day 1. Treatment repeats every 4-6 weeks in the absence of disease progression or unacceptable toxicity. Some patients with HER2/neu 3+ disease may also receive trastuzumab IV over 30-90 minutes weekly or every 3 weeks at the discretion of the treating physician. pegylated liposomal doxorubicin hydrochloride: Given IV cyclophosphamide: Given orally trastuzumab: Given IV
Measure Participants	30
Grade 3 adverse events	14 233.3%
Grade 4 adverse events	3 50%
At least one dose held or reduced	18 300%
Discontinued due to toxicity	8 133.3%

4. Secondary Outcome

Title	Treatment-related Toxicity (Phase I)
Description	Count of phase I participants with treatment related toxicity.
Time Frame	Up to 24 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Doxil 30 mg/m^2	Doxil 35 mg/m^2
Arm/Group Description	Patients receive oral cyclophosphamide once daily on days 1-28 and 30 mg/m^2 pegylated doxorubicin HCl liposome IV over 90 minutes on day 1. Treatment repeats every 4-6 weeks in the absence of disease progression or unacceptable toxicity. Some patients with HER2/neu 3+ disease may also receive trastuzumab IV over 30-90 minutes weekly or every 3 weeks at the discretion of the treating physician. pegylated liposomal doxorubicin hydrochloride: Given IV cyclophosphamide: Given orally trastuzumab: Given IV	Patients receive oral cyclophosphamide once daily on days 1-28 and 35 mg/m^2 pegylated doxorubicin HCl liposome IV over 90 minutes on day 1. Treatment repeats every 4-6 weeks in the absence of disease progression or unacceptable toxicity. Some patients with HER2/neu 3+ disease may also receive trastuzumab IV over 30-90 minutes weekly or every 3 weeks at the discretion of the treating physician. pegylated liposomal doxorubicin hydrochloride: Given IV cyclophosphamide: Given orally trastuzumab: Given IV
Measure Participants	3	3
Grade 2 Neutropenia	0 0%	1 4.2%
Grade 3 Neutropenia	0 0%	1 4.2%

5. Secondary Outcome

Title	Time to Progression (Phase II)
Description	Median time to progression. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions or new effusions.
Time Frame	Up to 2 years

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Phase II: Cyclophosphamide, Doxil, Trastuzumab
Arm/Group Description	Patients receive oral cyclophosphamide once daily on days 1-28 and pegylated doxorubicin HCl liposome IV over 90 minutes on day 1. Treatment repeats every 4-6 weeks in the absence of disease progression or unacceptable toxicity. Some patients with HER2/neu 3+ disease may also receive trastuzumab IV over 30-90 minutes weekly or every 3 weeks at the discretion of the treating physician. pegylated liposomal doxorubicin hydrochloride: Given IV cyclophosphamide: Given orally trastuzumab: Given IV
Measure Participants	22
Median (95% Confidence Interval) [months]	6.3

6. Secondary Outcome

Title	Progression-free Survival (Phase II)
Description	Kaplan-Meier estimate assessed at 18 months
Time Frame	18 months

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Phase II: Cyclophosphamide, Doxil, Trastuzumab
Arm/Group Description	Patients receive oral cyclophosphamide once daily on days 1-28 and pegylated doxorubicin HCl liposome IV over 90 minutes on day 1. Treatment repeats every 4-6 weeks in the absence of disease progression or unacceptable toxicity. Some patients with HER2/neu 3+ disease may also receive trastuzumab IV over 30-90 minutes weekly or every 3 weeks at the discretion of the treating physician. pegylated liposomal doxorubicin hydrochloride: Given IV cyclophosphamide: Given orally trastuzumab: Given IV
Measure Participants	22
Number (95% Confidence Interval) [progression free survival probability]	0.16

7. Secondary Outcome

Title	Overall Survival (Phase II)
Description	Kaplan-Meier estimate assessed at 18 months
Time Frame	18 months

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Phase II: Cyclophosphamide, Doxil, Trastuzumab
Arm/Group Description	Patients receive oral cyclophosphamide once daily on days 1-28 and pegylated doxorubicin HCl liposome IV over 90 minutes on day 1. Treatment repeats every 4-6 weeks in the absence of disease progression or unacceptable toxicity. Some patients with HER2/neu 3+ disease may also receive trastuzumab IV over 30-90 minutes weekly or every 3 weeks at the discretion of the treating physician. pegylated liposomal doxorubicin hydrochloride: Given IV cyclophosphamide: Given orally trastuzumab: Given IV
Measure Participants	22
Number (95% Confidence Interval) [survival probability]	0.49

8. Secondary Outcome

Title	Comparison of Clinical Benefit Rate in 2 Subgroups--heavily Pre-treated (1 or More Regimens for Advanced Disease) vs Less Heavily Pre-treated (no Regimens for Advanced Disease) (Phase II)
Description	Count of participants with a clinical benefit (i.e., complete response, partial response, and stable disease).
Time Frame	Up to 24 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Heavily Pre-treated	Less Heavily Pre-treated
Arm/Group Description	1 or more regimens for advanced disease	no regimens for advanced disease
Measure Participants	12	10
Count of Participants [Participants]	9 150%	7 29.2%

Adverse Events

Arm/Group Title	Cyclophosphamide, Doxil 30 mg/m^2, Trastuzumab		Cyclophosphamide, Doxil 35 mg/m^2, Trastuzumab
Arm/Group Description	Patients receive oral cyclophosphamide once daily on days 1-28 and 30 mg/m^2 pegylated doxorubicin HCl liposome IV over 90 minutes on day 1. Treatment repeats every 4-6 weeks in the absence of disease progression or unacceptable toxicity. Some patients with HER2/neu 3+ disease may also receive trastuzumab IV over 30-90 minutes weekly or every 3 weeks at the discretion of the treating physician. pegylated liposomal doxorubicin hydrochloride: Given IV cyclophosphamide: Given orally trastuzumab: Given IV		Patients receive oral cyclophosphamide once daily on days 1-28 and 35 mg/m^2 pegylated doxorubicin HCl liposome IV over 90 minutes on day 1. Treatment repeats every 4-6 weeks in the absence of disease progression or unacceptable toxicity. Some patients with HER2/neu 3+ disease may also receive trastuzumab IV over 30-90 minutes weekly or every 3 weeks at the discretion of the treating physician. pegylated liposomal doxorubicin hydrochloride: Given IV cyclophosphamide: Given orally trastuzumab: Given IV
All Cause Mortality
	Cyclophosphamide, Doxil 30 mg/m^2, Trastuzumab		Cyclophosphamide, Doxil 35 mg/m^2, Trastuzumab
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	/ (NaN)		/ (NaN)
Serious Adverse Events
	Cyclophosphamide, Doxil 30 mg/m^2, Trastuzumab		Cyclophosphamide, Doxil 35 mg/m^2, Trastuzumab
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	0/27 (0%)		0/3 (0%)
Other (Not Including Serious) Adverse Events
	Cyclophosphamide, Doxil 30 mg/m^2, Trastuzumab		Cyclophosphamide, Doxil 35 mg/m^2, Trastuzumab
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	27/27 (100%)		3/3 (100%)
Blood and lymphatic system disorders
Leukopenia	19/27 (70.4%)		3/3 (100%)
Anemia	8/27 (29.6%)		0/3 (0%)
Lymphopenia	1/27 (3.7%)		1/3 (33.3%)
Thrombocytopenia	5/27 (18.5%)		0/3 (0%)
Gastrointestinal disorders
Nausea	14/27 (51.9%)		1/3 (33.3%)
Vomitting	3/27 (11.1%)		0/3 (0%)
Constipation	3/27 (11.1%)		0/3 (0%)
Diarrhea	4/27 (14.8%)		0/3 (0%)
Gastric Reflux	2/27 (7.4%)		0/3 (0%)
Mucositis	4/27 (14.8%)		1/3 (33.3%)
Abdominal Pain	0/27 (0%)		1/3 (33.3%)
General disorders
Fatigue	12/27 (44.4%)		0/3 (0%)
Weight Loss	2/27 (7.4%)		1/3 (33.3%)
Infections and infestations
Neutropenia	18/27 (66.7%)		3/3 (100%)
Metabolism and nutrition disorders
Alkaline Phosphatase	2/27 (7.4%)		2/3 (66.7%)
ALT High	0/27 (0%)		1/3 (33.3%)
AST High	5/27 (18.5%)		1/3 (33.3%)
Low Hemoglobin	0/27 (0%)		1/3 (33.3%)
Hypocalcemia	3/27 (11.1%)		0/3 (0%)
Hypokalemia	2/27 (7.4%)		0/3 (0%)
Hyponatremia	4/27 (14.8%)		1/3 (33.3%)
Taste Alteration	0/27 (0%)		1/3 (33.3%)
Musculoskeletal and connective tissue disorders
Joint Pain	2/27 (7.4%)		0/3 (0%)
Respiratory, thoracic and mediastinal disorders
Cough	3/27 (11.1%)		0/3 (0%)
Skin and subcutaneous tissue disorders
Hand Foot Syndrome	7/27 (25.9%)		1/3 (33.3%)
Rash	7/27 (25.9%)		0/3 (0%)
Erythma	3/27 (11.1%)		0/3 (0%)

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

All Principal Investigators ARE employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.